Related Experiment Video
Updated: May 5, 2026
Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
Published on: September 8, 2021
Detecting mechanisms of acquired BRAF inhibitor resistance in melanoma
1Department of Medicine, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Abstract:
(V600)BRAF mutation was identified as an ideal target for clinical therapy due to its indispensable roles in supporting melanoma initiation and progression. Despite the fact that BRAF inhibitors (BRAFi) can elicit anti-tumor responses in the majority of treated patients and confer overall survival benefits, acquired drug resistance is a formidable obstacle to long-term management of the disease. Several aberrant events including RTK upregulation, NRAS mutation, mutant BRAF amplification or alternative splicing, and MEK mutation have been reported as acquired BRAFi resistance mechanisms. Clinially, detection of these resistance mechanisms help understand drug response patterns and help guide combinatorial therapeutic strategies. Therefore, quick and accurate diagnosis of the resistant mechanisms in tumor biopsies has become an important starting point for personalized therapy. In this chapter, we review the major acquired BRAFi resistance mechanisms, highlight their therapeutic implications, and provide the diagnostic methods from clinical samples.
Insights
BRAF inhibitors effectively treat melanoma but acquired resistance limits long-term management. Understanding resistance mechanisms like RTK upregulation and NRAS mutations is key for personalized therapy.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- The BRAF (V600) mutation is crucial in melanoma development and progression.
- BRAF inhibitors (BRAFi) offer survival benefits but acquired drug resistance is a major clinical challenge.
Purpose of the Study:
- To review acquired BRAF inhibitor resistance mechanisms in melanoma.
- To highlight the therapeutic implications of these resistance mechanisms.
- To outline diagnostic methods for identifying resistance in clinical samples.
Main Methods:
- Review of literature on acquired BRAF inhibitor resistance.
- Analysis of reported resistance mechanisms including RTK upregulation, NRAS mutations, BRAF amplification/alternative splicing, and MEK mutations.
- Discussion of diagnostic approaches for clinical tumor biopsies.
Main Results:
- Several molecular events contribute to acquired BRAF inhibitor resistance.
- Understanding these mechanisms is vital for predicting drug response.
- Accurate diagnosis guides personalized combinatorial therapeutic strategies.
Conclusions:
- Acquired resistance to BRAF inhibitors is a complex, multifactorial process.
- Identifying specific resistance mechanisms is essential for effective melanoma treatment.
- Diagnostic methods are crucial for tailoring personalized therapy and improving patient outcomes.
Related Concept Videos
02:56Treatment Resistant Cancers
02:53Adaptive Mechanisms in Cancer Cells
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...